# Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy

> **NCT05430828** · — · RECRUITING · sponsor: **Federico II University** · enrollment: 5000 (estimated)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** Repatha (evolocumab); Praluent (alirocumab)

## Key facts

- **NCT ID:** NCT05430828
- **Lead sponsor:** Federico II University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2020-03-07
- **Primary completion:** 2022-01-30
- **Final completion:** 2030-03-31
- **Target enrollment:** 5000 (ESTIMATED)
- **Last updated:** 2026-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05430828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05430828, "Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT05430828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*